NO20064576L - Pyrimidin-derivater for behandling av avvikende celle vekst - Google Patents

Pyrimidin-derivater for behandling av avvikende celle vekst

Info

Publication number
NO20064576L
NO20064576L NO20064576A NO20064576A NO20064576L NO 20064576 L NO20064576 L NO 20064576L NO 20064576 A NO20064576 A NO 20064576A NO 20064576 A NO20064576 A NO 20064576A NO 20064576 L NO20064576 L NO 20064576L
Authority
NO
Norway
Prior art keywords
cell growth
treatment
aberrant cell
pyrimidine derivatives
compounds
Prior art date
Application number
NO20064576A
Other languages
English (en)
Norwegian (no)
Inventor
Michael Joseph Luzzio
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064576(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20064576L publication Critical patent/NO20064576L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20064576A 2004-05-14 2006-10-09 Pyrimidin-derivater for behandling av avvikende celle vekst NO20064576L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
PCT/IB2005/001201 WO2005111023A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
NO20064576L true NO20064576L (no) 2006-11-07

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064576A NO20064576L (no) 2004-05-14 2006-10-09 Pyrimidin-derivater for behandling av avvikende celle vekst

Country Status (27)

Country Link
EP (1) EP1751143A1 (zh)
JP (1) JP4099212B2 (zh)
KR (1) KR100886990B1 (zh)
CN (2) CN102127058A (zh)
AP (1) AP2241A (zh)
AR (1) AR049097A1 (zh)
AU (2) AU2005243397A1 (zh)
BR (1) BRPI0511138A (zh)
CA (1) CA2566707A1 (zh)
CR (1) CR8749A (zh)
EA (1) EA200601796A1 (zh)
EC (1) ECSP066997A (zh)
GE (1) GEP20104875B (zh)
GT (1) GT200500113A (zh)
IL (1) IL178828A0 (zh)
MA (1) MA28583B1 (zh)
MX (1) MXPA06011890A (zh)
NL (2) NL1029045C2 (zh)
NO (1) NO20064576L (zh)
NZ (1) NZ550448A (zh)
PA (1) PA8632601A1 (zh)
PE (1) PE20060240A1 (zh)
TN (1) TNSN06370A1 (zh)
TW (1) TWI303635B (zh)
UY (1) UY28894A1 (zh)
WO (1) WO2005111023A1 (zh)
ZA (1) ZA200608394B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566531A1 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
AP2008004488A0 (en) * 2005-12-21 2008-06-30 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA97834C2 (ru) * 2007-04-18 2012-03-26 Пфайзер Продактс Инк. Производные сульфониламида для лечения анормального роста клеток
WO2009012421A1 (en) * 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
SI2300013T1 (en) * 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JPWO2014174745A1 (ja) * 2013-04-26 2017-02-23 国立大学法人京都大学 Eg5阻害剤
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1625121B1 (en) * 2002-12-20 2010-02-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
NL1029045C2 (nl) 2006-06-02
ZA200608394B (en) 2008-05-28
PE20060240A1 (es) 2006-04-01
CN102127058A (zh) 2011-07-20
EP1751143A1 (en) 2007-02-14
TWI303635B (en) 2008-12-01
UY28894A1 (es) 2005-12-30
WO2005111023A1 (en) 2005-11-24
NZ550448A (en) 2010-11-26
AU2005243397A1 (en) 2005-11-24
ECSP066997A (es) 2007-02-28
KR20070012477A (ko) 2007-01-25
MA28583B1 (fr) 2007-05-02
TNSN06370A1 (fr) 2008-02-22
NL1029045A1 (nl) 2005-11-15
CN1953974A (zh) 2007-04-25
AP2241A (en) 2011-06-01
JP2007537234A (ja) 2007-12-20
KR100886990B1 (ko) 2009-03-04
CR8749A (es) 2006-12-05
AP2006003790A0 (en) 2006-10-31
AU2009238255A1 (en) 2009-12-03
JP4099212B2 (ja) 2008-06-11
MXPA06011890A (es) 2006-12-14
AR049097A1 (es) 2006-06-28
NL1031845A1 (nl) 2006-07-31
NL1031845C2 (nl) 2006-11-23
PA8632601A1 (es) 2006-06-02
GEP20104875B (en) 2010-01-11
BRPI0511138A (pt) 2007-11-27
GT200500113A (es) 2006-01-10
IL178828A0 (en) 2007-03-08
CA2566707A1 (en) 2005-11-24
TW200539871A (en) 2005-12-16
EA200601796A1 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
NO20064576L (no) Pyrimidin-derivater for behandling av avvikende celle vekst
NO20054852L (no) GFAT inhibitorer
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
NO20050921L (no) Nye fysiologisk aktive substanser
NO20061432L (no) N3 alkylerte benzimidazolederivater som MEK-inhibitorer
NO20092033L (no) Nye forbindelser
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20083114L (no) Polysykliske indazolderivater som er ERK-inhibitorer
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20062130L (no) 4-(pyrazol-3-ylamino)pyrimidinderivater for anvendelse i behandling av kreft
NO20061506L (no) Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
NO20063928L (no) Substituerte kinolinforbindelser
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
NO20051303L (no) Nye benzoimidazolderivater nyttige som antiproliferative midler
NO20055688L (no) Organiske forbindelser
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
NO20065456L (no) Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
NO20070089L (no) DPP-IV inhibitorer
NO20055977L (no) Nye benzimidazolderivater
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application